Fiche publication
Date publication
février 2012
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CLEMENT-DUCHENE Christelle
,
Pr MARTINET Yves
Tous les auteurs :
Clement-Duchene C, Godbert B, Martinet Y
Lien Pubmed
Résumé
Lung cancer is the leading cause of cancer-related death. Targeting the vascular endothelial growth factor (VEGF) pathways in combination with standard chemotherapy can improve response rate and survival in non-small cell lung cancer. Since October 2006, a new class of drugs targeting angiogenesis has been introduced for the treatment of advanced lung cancer. Bevacizumab, an antibody directly targeting VEGF was the first agent to be approved. Other small molecule tyrosine kinase inhibitors targeting the VEGF receptor are also active in the treatment of advanced lung cancer and are currently under development. Most of these new drugs are well tolerated though potentially significant toxicities such as haemoptysis and hypertension have been observed. This article will review these new-targeted anti-angiogenic agents with a focus on their use in lung cancer and on their important side effects.
Référence
Rev Mal Respir. 2012 Feb;29(2):161-77
